The abstract is read at the publisher; the summary is JClub's.
ESR1-L536 mutations in ER-positive metastatic breast tumors are linked to reduced elacestrant benefit, with longer hazard and shorter time-on-treatment (HR=2.089, p=0.001).
- Why it matters: Variant-specific effects of ESR1 on SERD response are unclear, limiting biomarker precision for elacestrant in metastatic breast cancer.
- What they did: Tumors sequenced at Caris Life Sciences (n=3,344; RNA-seq subset n=1,663) were analyzed using Cox models on insurance-claims time-on-treatment for elacestrant.
- The result: ESR1-L536 tumors showed lower GREB1 expression and less estrogen-response pathway enrichment, and multiple ESR1 mutations predicted shorter time-on-treatment (adjusted HR=1.62, p=0.038).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.